{"id":"https://openalex.org/W4361902203","doi":"https://doi.org/10.1158/1078-0432.22442357","title":"Supplementary Data from A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies","display_name":"Supplementary Data from A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361902203","doi":"https://doi.org/10.1158/1078-0432.22442357"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22442357","doi":"https://doi.org/10.1158/1078-0432.22442357","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22442357","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_A_Phase_I_Study_of_7-_i_t_i_-Butyldimethylsilyl-10-Hydroxycamptothecin_in_Adult_Patients_with_Refractory_or_Metastatic_Solid_Malignancies/22442357/1/files/39893246.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_A_Phase_I_Study_of_7-_i_t_i_-Butyldimethylsilyl-10-Hydroxycamptothecin_in_Adult_Patients_with_Refractory_or_Metastatic_Solid_Malignancies/22442357/1/files/39893246.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030064179","display_name":"Susanne M. Arnold","orcid":"https://orcid.org/0000-0001-6542-9551","observed_orcids":["https://orcid.org/0000-0001-6542-9551"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susanne M. Arnold","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110187618","display_name":"John J. Rinehart","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John J. Rinehart","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013968242","display_name":"Eleftheria Tsakalozou","orcid":"https://orcid.org/0000-0003-1993-8528","observed_orcids":["https://orcid.org/0000-0003-1993-8528"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eleftheria Tsakalozou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071938679","display_name":"John Randall Eckardt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John R. Eckardt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111813748","display_name":"Scott Z. Fields","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Z. Fields","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036233525","display_name":"Brent J. Shelton","orcid":"https://orcid.org/0000-0002-3002-5300","observed_orcids":["https://orcid.org/0000-0002-3002-5300"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brent J. Shelton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103737582","display_name":"Philip A. DeSimone","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip A. DeSimone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060749148","display_name":"Bryan K. Kee","orcid":"https://orcid.org/0000-0001-5553-2213","observed_orcids":["https://orcid.org/0000-0001-5553-2213"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bryan K. Kee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079657944","display_name":"Jeffrey A. Moscow","orcid":"https://orcid.org/0000-0002-0479-1693","observed_orcids":["https://orcid.org/0000-0002-0479-1693"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey A. Moscow","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5008062466","display_name":"Markos L. Leggas","orcid":"https://orcid.org/0000-0003-4314-4533","observed_orcids":["https://orcid.org/0000-0003-4314-4533"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Markos Leggas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13105","display_name":"Synthesis and pharmacology of benzodiazepine derivatives","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/camptothecin-derivatives","display_name":"camptothecin derivatives","score":0.8240000009536743},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.8980000019073486},{"id":"https://openalex.org/keywords/refractory-solid-tumors","display_name":"refractory solid tumors","score":0.921999990940094},{"id":"https://openalex.org/keywords/anticancer-drug-toxicity","display_name":"anticancer drug toxicity","score":0.49399998784065247}],"concepts":[{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.8061075210571289},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48501846194267273},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46230924129486084},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.45605796575546265},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4463622570037842},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.41628628969192505},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35091954469680786},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.34416311979293823},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.228131502866745},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.16104739904403687},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.13088524341583252},{"id":"https://openalex.org/C191897082","wikidata":"https://www.wikidata.org/wiki/Q11467","display_name":"Metallurgy","level":1,"score":0.05712920427322388},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22442357","doi":"https://doi.org/10.1158/1078-0432.22442357","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22442357","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_A_Phase_I_Study_of_7-_i_t_i_-Butyldimethylsilyl-10-Hydroxycamptothecin_in_Adult_Patients_with_Refractory_or_Metastatic_Solid_Malignancies/22442357/1/files/39893246.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22442357.v1","doi":"https://doi.org/10.1158/1078-0432.22442357.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22442357.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22442357","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Data_from_A_Phase_I_Study_of_7-_i_t_i_-Butyldimethylsilyl-10-Hydroxycamptothecin_in_Adult_Patients_with_Refractory_or_Metastatic_Solid_Malignancies/22442357","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22442357","doi":"https://doi.org/10.1158/1078-0432.22442357","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22442357","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_A_Phase_I_Study_of_7-_i_t_i_-Butyldimethylsilyl-10-Hydroxycamptothecin_in_Adult_Patients_with_Refractory_or_Metastatic_Solid_Malignancies/22442357/1/files/39893246.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9476000070571899,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361902203.pdf","grobid_xml":"https://content.openalex.org/works/W4361902203.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361817369","https://openalex.org/W2147089783","https://openalex.org/W2258818306","https://openalex.org/W2472379003","https://openalex.org/W2604179124","https://openalex.org/W7172261707","https://openalex.org/W2249713864","https://openalex.org/W2416716456","https://openalex.org/W2364863434","https://openalex.org/W4389921006"],"abstract_inverted_index":{"Supplementary":[0],"Data":[1],"from":[2],"A":[3],"Phase":[4],"I":[5],"Study":[6],"of":[7],"7-t-Butyldimethylsilyl-10-Hydroxycamptothecin":[8],"in":[9],"Adult":[10],"Patients":[11],"with":[12],"Refractory":[13],"or":[14],"Metastatic":[15],"Solid":[16],"Malignancies":[17]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}